Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5962946, 8 pages
http://dx.doi.org/10.1155/2016/5962946
Research Article

Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis

1Department of Biochemical Diagnostics, Medical University of Bialystok, 15-089 Bialystok, Poland
2Department of Esthetic Medicine, Medical University of Bialystok, 15-089 Bialystok, Poland
3Department of Hematological Diagnostics, Medical University of Bialystok, 15-089 Bialystok, Poland
4Department of Surgery, Public Health Hospital, 19-100 Monki, Poland

Received 12 April 2016; Accepted 12 June 2016

Academic Editor: Czar L. Gaston

Copyright © 2016 Monika Zajkowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Trichopoulos, H.-O. Adami, A. Ekbom, C.-C. Hsieh, and P. Lagiou, “Early life events and conditions and breast cancer risk: from epidemiology to etiology,” International Journal of Cancer, vol. 122, no. 3, pp. 481–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Harris, H. Fritsche, R. Mennel et al., “American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5287–5312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Hicklin and L. M. Ellis, “Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 1011–1027, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ławicki, M. Zajkowska, E. Głażewska, G. Będkowska, and M. Szmitkowski, “Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer,” OncoTargets and Therapy, vol. 9, pp. 911–919, 2016. View at Publisher · View at Google Scholar
  6. A. Veeravagu, A. R. Hsu, W. Cai, L. C. Hou, V. C. K. Tse, and X. Chen, “Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy,” Recent Patents on Anti-Cancer Drug Discovery, vol. 2, no. 1, pp. 59–71, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Chockalingam and S. S. Ghosh, “Macrophage colony-stimulating factor and cancer: a review,” Tumor Biology, vol. 35, no. 11, pp. 10635–10644, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Ławicki, E. K. Głażewska, M. Sobolewska, G. E. Będkowska, and M. Szmitkowski, “Plasma levels and diagnostic utility of macrophage colony-stimulating factor, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 as new biomarkers of breast cancer,” Annals of Laboratory Medicine, vol. 36, no. 3, pp. 223–229, 2016. View at Publisher · View at Google Scholar
  9. S. K. Chambers, B. M. Kacinski, C. M. Ivins, and M. L. Carcangiu, “Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1,” Clinical Cancer Research, vol. 3, no. 6, pp. 999–1007, 1997. View at Google Scholar · View at Scopus
  10. W. Zhang, X. Zheng, and X. Wang, “Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer,” American Journal of Cancer Research, vol. 5, no. 9, pp. 2788–2798, 2015. View at Google Scholar
  11. Q. Wang, X. Li, S. Ren et al., “Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer,” PLoS ONE, vol. 10, no. 4, Article ID e0122792, 2015. View at Publisher · View at Google Scholar
  12. Y. Park, J. H. Lee, D. J. Hong, E. Y. Lee, and H. S. Kim, “Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases,” Clinical Biochemistry, vol. 44, no. 10-11, pp. 884–888, 2011. View at Publisher · View at Google Scholar
  13. D. Cheng, B. Liang, and Y. Li, “Serum Vascular Endothelial Growth Factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer,” PLoS ONE, vol. 8, no. 2, Article ID e55309, 2013. View at Publisher · View at Google Scholar
  14. D. J. Park, N. J. Thomas, C. Yoon, and S. S. Yoon, “Vascular endothelial growth factor a inhibition in gastric cancer,” Gastric Cancer, vol. 18, no. 1, pp. 33–42, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Goi, T. Nakazawa, Y. Hirono, and A. Yamaguchi, “The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer,” Oncotarget, vol. 6, no. 8, pp. 6053–6061, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Ławicki, G. E. Będkowska, E. Gacuta-Szumarska, and M. Szmitkowski, “The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors,” Journal of Ovarian Research, vol. 6, no. 1, article 45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. G. E. Będkowska, S. Ławicki, and M. Szmitkowski, “Molecular markers of carcinogenesis in the diagnostics of cervical cancer,” Postępy Higieny i Medycyny Doświadczalnej, vol. 63, pp. 99–105, 2009. View at Google Scholar · View at Scopus
  18. R. Zhou, Y. Zhou, and Z. Chen, “Exploration of macrophage colony-stimulating factor as a new type of tumor marker,” Biomedical Reports, vol. 1, no. 6, pp. 845–849, 2013. View at Google Scholar
  19. G. Vasiliades, N. Kopanakis, M. Vasiloglou et al., “Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer,” International Journal of Biological Markers, vol. 27, no. 3, pp. e186–e194, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ławicki, E. Gacuta-Szumarska, G. E. Będkowska, and M. Szmitkowski, “Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients,” Growth Factors, vol. 30, no. 6, pp. 357–366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. G. E. Będkowska, S. Ławicki, E. Gacuta, P. Pawłowski, and M. Szmitkowski, “M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients,” Journal of Ovarian Research, vol. 8, article 27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ławicki, G. E. Będkowska, E. Gacuta-Szumarska, P. Knapp, and M. Szmitkowski, “The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients,” Polski Merkuriusz Lekarski, vol. 25, no. 145, pp. 38–42, 2008. View at Google Scholar · View at Scopus
  23. S. Ławicki, G. E. Będkowska, E. Gacuta-Szumarska, and M. Szmitkowski, “Hematopoietic cytokines as tumor markers in gynecological malignancies: a multivariate analysis with ROC curve in endometrial cancer patients,” Growth Factors, vol. 30, no. 1, pp. 29–36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Motawa El Husseini, E. Fatmaelzahraa Hussein, M. Abdelghani, and M. Basma Abdelghany, “Clinical significance of TGF alpha, TGF beta1 and VEGF in Sera of Egyptian patients with breast cancer,” The Egyptian Journal of Hospital Medicine, vol. 52, pp. 555–565, 2013. View at Publisher · View at Google Scholar
  25. M. Kozłowski, W. Laudański, B. Mroczko, M. Szmitkowski, R. Milewski, and G. Łapuć, “Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients,” Advances in Medical Sciences, vol. 58, no. 2, pp. 227–234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Cao, S.-F. Sun, D. Lv, Z.-B. Chen, Q.-L. Ding, and Z.-C. Deng, “Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 4, pp. 2443–2446, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Y. Zhang, Y. Li, J. Z. Wu et al., “Detection of serum VEGF and MMP-9 levels by luminex multiplexed assays in patients with breast infiltrative ductal carcinoma,” Experimental and Therapeutic Medicine, vol. 8, no. 1, pp. 175–180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ławicki, G. E. Będkowska, and M. Szmitkowski, “VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve,” Growth Factors, vol. 31, no. 3, pp. 98–105, 2013. View at Publisher · View at Google Scholar · View at Scopus